Compare GHC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHC | TVTX |
|---|---|---|
| Founded | 1877 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.3B |
| IPO Year | 1994 | 2013 |
| Metric | GHC | TVTX |
|---|---|---|
| Price | $1,182.66 | $56.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $40.62 |
| AVG Volume (30 Days) | 17.6K | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 66.47 | N/A |
| Revenue | ★ $2,932,099,000.00 | N/A |
| Revenue This Year | $7.73 | $44.76 |
| Revenue Next Year | $4.37 | $35.51 |
| P/E Ratio | $17.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $882.21 | $15.03 |
| 52 Week High | $1,224.76 | $60.10 |
| Indicator | GHC | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 61.02 |
| Support Level | $1,080.80 | $54.87 |
| Resistance Level | $1,197.19 | $60.10 |
| Average True Range (ATR) | 34.90 | 2.20 |
| MACD | 0.91 | -0.55 |
| Stochastic Oscillator | 74.16 | 48.94 |
Graham Holdings Company is a diversified holding company with operations spanning educational services, television broadcasting, healthcare, manufacturing, automotive dealerships, and other businesses. The Company's education activities are conducted through Kaplan, whose services include academic preparation programs for international students, English-language programs, exam preparation, and career and academic advisement. These services are provided to students, schools, and colleges, both domestically and outside the United States. It operates through seven reportable segments: Kaplan International, Kaplan Higher Education, Kaplan Supplemental Education, Television Broadcasting, CSI, Manufacturing and Automotive, with key revenue coming from the Education and Automotive segments.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.